As of March 23, 2026, Protalix BioTherapeutics's top three insider holders are Pharma Technologies Ltd. Dexcel (TenPercentOwner, 3.64Mn shares), Dror Bashan (President And Ceo, 2.34Mn shares), Eyal Rubin (Sr. Vp And Cfo, 660.91K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Pharma Technologies Ltd. Dexcel | 3,637,314 | 0 | 03 Jun, 2021 | |
| Dror Bashan | President And Ceo | 0 | 2,344,418 | 04 Sep, 2025 |
| Eyal Rubin | Sr. Vp And Cfo | 0 | 660,909 | 05 Nov, 2024 |
| Aharon Schwartz | 303,000 | 0 | 12 Aug, 2025 | |
| Yaron Naos | Sr. Vp, Operations | 0 | 225,817 | 04 Sep, 2025 |
| Dror Bashan | President And Ceo | 188,516 | 0 | 23 Dec, 2025 |
| Yael Hayon | Vp, Research Development | 0 | 35,115 | 17 Aug, 2023 |
| Eliot Forster | 0 | 7,500 | 04 Sep, 2025 | |
| Pol F Boudes | 0 | 7,500 | 04 Sep, 2025 | |
| Amos Bar-Shalev | 0 | 7,500 | 04 Sep, 2025 | |
| Aharon Schwartz | 0 | 7,500 | 04 Sep, 2025 | |
| Christian Elze | 0 | 7,500 | 04 Sep, 2025 | |
| Zvi Shmuel Ben | 0 | 7,500 | 04 Sep, 2025 | |
| Gwen A Melincoff | 0 | 7,500 | 04 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Dec, 2025 | Dror Bashan | Common Stock | A | 56,000 | $1.81 | 188,516 | D | P |
| 18 Nov, 2025 | Amos Bar-Shalev | Common Stock | D | 168 | $1.87 | 0 | D | S |
| 03 Sep, 2025 | Eliot Forster | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Gwen A Melincoff | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Pol F Boudes | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Zvi Shmuel Ben | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Aharon Schwartz | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Yaron Naos | Common Stock | A | 25,000 | - | 225,817 | I | A |
| 03 Sep, 2025 | Christian Elze | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Dror Bashan | Common Stock | A | 195,000 | - | 2,344,418 | I | A |
| 03 Sep, 2025 | Amos Bar-Shalev | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Gwen A Melincoff | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Zvi Shmuel Ben | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Christian Elze | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Eliot Forster | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Aharon Schwartz | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Yaron Naos | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 03 Sep, 2025 | Amos Bar-Shalev | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Dror Bashan | Stock Option (Right to Buy) | A | 340,000 | $0.00 | 340,000 | D | A |
| 03 Sep, 2025 | Pol F Boudes | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |